Irinotecan hydrochloride
(Redirected from Camptosar)
What is Irinotecan hydrochloride?[edit | edit source]
- Irinotecan hydrochloride (Camptosar) is a topoisomerase inhibitor used alone or with other drugs to treat colon cancer or rectal cancer that has spread to other parts of the body or has come back after treatment with fluorouracil.
What are the uses of this medicine?[edit | edit source]
Irinotecan hydrochloride (Camptosar) used for:
- First-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum.
- Patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.
How does this medicine work?[edit | edit source]
- Irinotecan is a derivative of camptothecin.
- Camptothecins interact specifically with the enzyme topoisomerase I, which relieves torsional strain in DNA by inducing reversible single-strand breaks.
- Irinotecan hydrochloride blocks certain enzymes needed for cell division and DNA repair, and it may kill cancer cells.
- It is a type of topoisomerase inhibitor and a type of camptothecin analog.
Who Should Not Use this medicine ?[edit | edit source]
This medicine cannot be used in patients with:
- a known hypersensitivity to the drug or its excipients.
What drug interactions can this medicine cause?[edit | edit source]
- Do not administer strong CYP3A4 inducers with Camptosar.
- Do not administer strong CYP3A4 inhibitors with Camptosar.
Is this medicine FDA approved?[edit | edit source]
- Irinotecan was approved for medical use in the United States in 1996.
How should this medicine be used?[edit | edit source]
- It is recommended that patients receive premedication with antiemetic agents.
Recommended dosage and Administration: Colorectal cancer combination regimen 1:
- Camptosar 125 mg/m2 intravenous infusion over 90 minutes on days 1, 8,15, 22 with LV 20 mg/m2 intravenous bolus infusion on days 1, 8, 15, 22 followed by 5-FU intravenous bolus infusion on days 1, 8, 15, 22 every 6 weeks.
Colorectal cancer combination regimen 2:
- Camptosar 180 mg/m2 intravenous infusion over 90 minutes on days 1, 15, 29 with LV 200 mg/m2 intravenous infusion over 2 hours on days 1, 2, 15, 16, 29, 30 followed by 5-FU 400 mg/m2 intravenous bolus infusion on days 1, 2, 15, 16, 29, 30 and 5-FU 600 mg/m2 intravenous infusion over 22 hours on days 1, 2, 15, 16, 29, 30.
Colorectal cancer single agent regimen 1:
- Camptosar 125 mg/m2 intravenous infusion over 90 minutes on days 1, 8, 15, 22 then 2-week rest.
Colorectal cancer single agent regimen 2:
- Camptosar 350 mg/m2 intravenous infusion over 90 minutes on day 1 every 3 weeks.
What are the dosage forms and brand names of this medicine?[edit | edit source]
This medicine is available in fallowing doasage form:
- As Injection: 40 mg/2 mL (20 mg/mL), 100 mg/5 mL (20 mg/mL), and 300 mg/15 mL (20 mg/mL) solution in a single-dose vial.
This medicine is available in fallowing brand namesː
- Camptosar
What side effects can this medication cause?[edit | edit source]
The most common side effects of this medicine include: In combination therapy:
- nausea, vomiting, abdominal pain, diarrhea, constipation, anorexia, mucositis, neutropenia, leukopenia (including lymphocytopenia), anemia, thrombocytopenia, asthenia, pain, fever, infection, abnormal bilirubin, alopecia
In single agent therapy:
- nausea, vomiting, abdominal pain, diarrhea, constipation, anorexia, neutropenia, leukopenia (including lymphocytopenia), anemia, asthenia, fever, body weight decreasing, alopecia
What special precautions should I follow?[edit | edit source]
- Early diarrhea (occurring during or shortly after infusion of Camptosar) is usually transient and may be accompanied by cholinergic symptoms. Consider prophylactic or therapeutic administration of 0.25 mg to 1 mg of intravenous or subcutaneous atropine (unless clinically contraindicated). Late diarrhea (generally occurring more than 24 hours after administration of Camptosar) can occur. Monitor and replace fluid and electrolytes. Treat with loperamide. Use antibiotic support for ileus and fever. Interrupt Camptosar and reduce subsequent doses if severe diarrhea occurs.
- Camptosar can cause severe myelosuppression. Manage promptly with antibiotic support. Interrupt Camptosar and reduce subsequent doses if necessary.
- Individuals with UGT1A1*28/*28, or *6/*6, or *6/*28 genotypes are at increased risk for severe neutropenia during Camptosar treatment.
- Hypersensitivity reactions including severe anaphylactic or anaphylactoid reactions have been observed. Discontinue Camptosar if this occurs.
- Rare cases of renal impairment and acute renal failure have been identified, usually in patients who became volume depleted from severe vomiting and/or diarrhea.
- Interstitial Pulmonary Disease (IPD)-like events, including fatalities, have occurred. Interrupt for new or progressive dyspnea, cough, and fever pending evaluation. If IPD diagnosed, discontinue and institute appropriate treatment as needed.
- Camptosar should not be used in combination with a regimen of 5-FU/LV administered for 4–5 consecutive days every 4 weeks outside of a clinical study.
- Camptosar can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception. Advise male patients with female partners of reproductive potential to use condoms.
- In clinical trials, Camptosar has not been administered to patients with serum bilirubin > 2.0 mg/dL, or transaminases > 3 times ULN if no liver metastases, or transaminases > 5 times ULN if liver metastases. With the weekly dosage schedule, patients with total bilirubin levels 1.0–2.0 mg/dL had greater likelihood of grade 3–4 neutropenia.
What to do in case of emergency/overdose?[edit | edit source]
Symptoms of overdosage may include:
- severe neutropenia
- severe diarrhea
Management of overdosage:
- There is no known antidote for overdosage of Camptosar.
- Maximum supportive care should be instituted to prevent dehydration due to diarrhea and to treat any infectious complications.
Can this medicine be used in pregnancy?[edit | edit source]
- Based on findings from animal studies and its mechanism of action, Camptosar can cause fetal harm when administered to a pregnant woman.
- Advise pregnant women of the potential risk to a fetus.
Can this medicine be used in children?[edit | edit source]
- The effectiveness of irinotecan in pediatric patients has not been established.
What are the active and inactive ingredients in this medicine?[edit | edit source]
Active ingredients:
- IRINOTECAN HYDROCHLORIDE
Inactive ingredients:
- LACTIC ACID, UNSPECIFIED FORM
- SODIUM HYDROXIDE
- HYDROCHLORIC ACID
Who manufactures and distributes this medicine?[edit | edit source]
- Packager: Pharmacia & Upjohn Company LLC
What should I know about storage and disposal of this medication?[edit | edit source]
- Store at controlled room temperature 15°C to 30°C (59° to 86°F).
- Protect from light.
- Keep the vial in the carton until the time of use.
- Inspect the vial for damage and visible signs of leaks before removing from the carton.
- If damaged, incinerate the unopened package.
- Camptosar is a hazardous drug.
- Follow special handling and disposal procedures.
Irinotecan hydrochloride Resources | |
---|---|
|
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Deepika vegiraju